Did Pfizer discontinue Vizimpro (dacomitinib) in the U.S. in 2024?
No. The information provided here does not say that Pfizer discontinued Vizimpro (dacomitinib) in the United States in 2024. The product’s discontinuation status can’t be confirmed from the available details.
If you’re seeing a “discontinued” message, it’s usually tied to one of these situations rather than a full U.S. market withdrawal: a specific strength/package becoming temporarily unavailable, an inventory or distribution change, or a label/packaging update.
Could it be a shortage or a specific strength that’s unavailable?
That’s a common cause of confusion. Even when a drug is still marketed, certain tablets/strengths (or a particular NDC) can be:
- out of stock,
- on limited distribution,
- delayed in supply,
- or transitioning between manufacturers/packagers.
To verify, you’d need the exact strength (e.g., 15 mg, 30 mg, 45 mg) and the NDC from the bottle or prescription.
What’s the fastest way to confirm whether it’s truly discontinued?
Check one of these:
- The U.S. FDA’s drug availability/supply notifications (if present for the product).
- Pfizer’s drug/distribution or product-pipeline communications (if they issued one).
- The NDC-level status via your pharmacy supplier.
If you paste the exact wording you saw (and the strength/NDC), I can help interpret whether it sounds like a true discontinuation versus an availability issue.
If Vizimpro is temporarily unavailable, what are typical alternatives?
For patients on dacomitinib, the most straightforward alternative depends on the reason it can’t be obtained (stock vs. true withdrawal) and the cancer’s biomarker status. In practice, clinicians often consider other EGFR tyrosine kinase inhibitors or treatment adjustments, but the right option depends on the individual regimen and prior therapy.
What I need from you to give a precise answer
Reply with:
1) the exact strength (and whether it’s tablets),
2) the NDC number (from the bottle),
3) where you saw “discontinued” (pharmacy label, prescriber notice, online listing, or FDA/pharmacist alert),
4) the date.
Then I can tell you whether it points to a full U.S. discontinuation or a narrower availability/distribution change.